A Prospective, Single-arm Exploratory Trail of Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Sponsor study identifier
interventional
40
1 country
1
Study Start
March 1, 2024
Actual (reported)Primary Completion
March 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 20, 2024
Actual (reported)February 28, 2024
Actual (reported)March 1, 2024
Actual (reported)March 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
1-year EFS rate
1-year event-free survival rate
Up to approximately 3 years
R0 Resection rate
Up to approximately 3 years
EFS
Up to approximately 3 years
RFS
Up to approximately 3 years
OS
Up to approximately 3 years
Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Adebrelimab, Apatinib, Gemcitabine, cisplatin
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, China/Guangdong, China
Yajin Chen
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Submitted
February 20, 2024
First Posted
February 28, 2024
Study Start
March 1, 2024
Actual (reported)Primary Completion
March 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 23, 2024
Record last verified: 2024-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: